Investigational Drug Information for Idasanutlin
✉ Email this page to a colleague
What is the development status for investigational drug Idasanutlin?
Idasanutlin is an investigational drug.
There have been 14 clinical trials for Idasanutlin.
The most recent clinical trial was a Phase 1 trial, which was initiated on December 30th 2015.
The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Leukemia, Myeloid. The leading clinical trial sponsors are Hoffmann-La Roche, German Cancer Aid, and German Cancer Research Center.
There are twenty-seven US patents protecting this investigational drug and three hundred international patents.
Summary for Idasanutlin
| US Patents | 27 |
| International Patents | 300 |
| US Patent Applications | 249 |
| WIPO Patent Applications | 159 |
| Japanese Patent Applications | 23 |
| Clinical Trial Progress | Phase 1 (2015-12-30) |
| Vendors | 60 |
Recent Clinical Trials for Idasanutlin
| Title | Sponsor | Phase |
|---|---|---|
| Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Hoffmann-La Roche | Phase 2 |
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Le | Hoffmann-La Roche | Phase 1/Phase 2 |
| A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Comple | Hoffmann-La Roche | Phase 1/Phase 2 |
Clinical Trial Summary for Idasanutlin
Top disease conditions for Idasanutlin
Top clinical trial sponsors for Idasanutlin
US Patents for Idasanutlin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Idasanutlin | ⤷ Try a Trial | Treatment of ophthalmic conditions by selectively removing senescent cells from the eye | Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) | ⤷ Try a Trial |
| Idasanutlin | ⤷ Try a Trial | Compounds targeting proteins, compositions, methods, and uses thereof | Biotheryx, Inc. (Chappaqua, NY) | ⤷ Try a Trial |
| Idasanutlin | ⤷ Try a Trial | Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids | Cantex Pharmaceuticals, Inc. (Weston, FL) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Idasanutlin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Idasanutlin | Australia | AU2015211021 | 2034-01-28 | ⤷ Try a Trial |
| Idasanutlin | Australia | AU2020244600 | 2034-01-28 | ⤷ Try a Trial |
| Idasanutlin | Australia | AU2022256167 | 2034-01-28 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
